Quarterly ResultAug 3, 2026, 07:31 AM
Twist Bioscience Q3 Revenue $118.4M, Raises FY26 Guidance to $456-457M
AI Summary
Twist Bioscience reported strong fiscal third quarter 2026 financial results, with revenue increasing 23% year-over-year to $118.4 million, marking its fourteenth consecutive quarter of sequential growth. The company raised its full fiscal year 2026 revenue guidance to $456-$457 million and reiterated its expectation to achieve adjusted EBITDA breakeven in Q4 FY26. Despite the revenue growth and improved gross margin, the company reported a net loss of $(35.1) million, compared to a net income in the prior year which included a significant gain from a business spin-out.
Key Highlights
- Q3 FY26 revenue grew 23% to $118.4 million, marking 14th consecutive sequential growth.
- FY26 revenue guidance raised to $456-$457 million, up $12 million at midpoint.
- Q3 gross margin improved to 52.8%, a 120 basis point sequential increase.
- Q3 DSPS revenue increased 39% to $56.6 million.
- Q3 NGS revenue increased 12% to $61.8 million.
- Reiterated Q4 FY26 adjusted EBITDA breakeven target.
- Q3 net loss was $(35.1) million, or $(0.56) per diluted share.
- Cash, cash equivalents, and short-term investments totaled $167 million.
Price Impact
More from TWST